Global Lupus Therapeutic Market 2017-2021


◆タイトル:Global Lupus Therapeutic Market 2017-2021
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆資料形式:PDF / 英語
Single User(1名利用)USD3,500 ⇒換算¥381,500見積依頼/購入/質問フォーム
Five User(~5名利用)USD4,000 ⇒換算¥436,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD5,000 ⇒換算¥545,000見積依頼/購入/質問フォーム
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。



About Lupus TherapeuticLupus is a chronic autoimmune disease in which the body’s immune system becomes hyperactive and attacks normal, healthy tissue. This results in symptoms such as inflammation, swelling, and damage to joints, skin, kidneys, blood, the heart, and lungs. Systemic lupus erythematosus (SLE) is a major disease, which is followed by lupus nephritis at the later stages. Only one drug is approved specifically for the treatment of lupus disorders and the majority of other drugs are off-label based on symptoms. Due to a strong pipeline, the market is expected for more approved drugs for lupus disorders in future.

Technavio’s analysts forecast the global lupus therapeutic market to grow at a CAGR of 9.74% during the period 2017-2021.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global lupus therapeutic market for 2017-2021. To calculate the market size, the report considers both generic and branded drug market.

The market is divided into the following segments based on geography:
• Americas

Technavio’s report, Global Lupus Therapeutic Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• F.Hoffmann-La Roche
• GlaxoSmithKline
• Medlmmune
• Pfizer

[Other prominent vendors]
• ADMA Biologics
• Amgen
• Anthera Pharmaceuticals
• Bayer HealthCare
• Biogen
• Biotest
• Bristol-Myers Squibb
• Celgene
• Immunomedics
• Kedrion Biopharma
• LFB Group
• Merck
• Novartis
• Shire
• Takeda Pharmaceuticals

[Market driver]
• High prevalence rate
• For a full, detailed list, view our report

[Market challenge]
• Complexity of disease
• For a full, detailed list, view our report

[Market trend]
• Regenerative therapeutic technologies
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

*** You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.


Table of Contents
PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

PART 05: An overview of lupus disease

PART 06: Market landscape
• Market overview
• Five forces analysis

PART 07: Pipeline landscape

PART 08: Market segmentation by drug class
• Anti-inflammatory drugs
• Corticosteroids
• Immunosuppressant drugs
• Antimalarial drugs
• BLyS-specific inhibitors
• Biologicals
• Others

PART 09: Geographical segmentation
• Lupus therapeutics market in Americas
• Lupus therapeutics market in EMEA
• Lupus therapeutics market in APAC

PART 10: Decision framework

PART 11: Drivers and challenges
• Market drivers
• Market challenges

PART 12: Market trends
• Regenerative therapeutic technologies
• Inorganic growth strategies
• Government initiatives

PART 13: Vendor landscape
• Competitive scenario

PART 14: Key vendor analysis
• F. Hoffmann-La Roche
• GlaxoSmithKline
• MedImmune
• Pfizer
• Other prominent vendors

PART 15: Appendix
• List of abbreviations

[List of Exhibits]
Exhibit 01: Signs and symptoms in SLE
Exhibit 02: Global lupus therapeutic market snapshot
Exhibit 03: Global lupus therapeutics market 2016-2021 ($ millions)
Exhibit 04: Opportunity analysis in global lupus therapeutic market
Exhibit 05: Five forces analysis
Exhibit 06: Pipeline analysis
Exhibit 07: Key clinical trials
Exhibit 08: Segmentation of global lupus therapeutic market by drug class 2016
Exhibit 09: Global lupus anti-inflammatory therapeutics market 2016-2021 ($ millions)
Exhibit 10: Global lupus corticosteroid drug market 2016-2021 ($ millions)
Exhibit 11: Global lupus immunosuppressant drugs market 2016-2021 ($ millions)
Exhibit 12: Global Iupus antimalarial drug market 2016-2021 ($ millions)
Exhibit 13: Global lupus market for BLyS-specific inhibitors drug segment 2016-2021 ($ millions)
Exhibit 14: Global lupus biologicals market 2016-2021 ($ millions)
Exhibit 15: Global Iupus other therapeutics market 2016-2021 ($ millions)
Exhibit 16: Segmentation of global lupus therapeutics market by geography 2016 and 2021
Exhibit 17: Global lupus therapeutics market revenue by geography 2016-2021 ($ millions)
Exhibit 18: Market scenario in Americas
Exhibit 19: Lupus therapeutics market in Americas 2016-2021 ($ millions)
Exhibit 20: Market scenario in EMEA
Exhibit 21: Lupus therapeutics market in EMEA 2016-2021 ($ millions)
Exhibit 22: Market scenario in APAC
Exhibit 23: Lupus therapeutic market in APAC 2016-2021 ($ millions)
Exhibit 24: Diagnostic tools for lupus disorders
Exhibit 25: Various drug classes used as off-label treatment for lupus disorders
Exhibit 26: Various complex symptoms associated with lupus disorder
Exhibit 27: Various side effects associated with lupus treatment
Exhibit 28: Pipeline of regenerative medicines for lupus disorders
Exhibit 29: Aims of action plans by CDC
Exhibit 30: Competitive structure analysis of global lupus therapeutics market 2016
Exhibit 31: Competitive factors of global lupus therapeutics market
Exhibit 32: Market penetration of various vendors worldwide 2016
Exhibit 33: Strategic success factors of companies in global lupus therapeutics market
Exhibit 34: F. Hoffmann-La Roche: Key highlights
Exhibit 35: F. Hoffmann-La Roche: Strength assessment
Exhibit 36: F. Hoffmann-La Roche: Strategy assessment
Exhibit 37: F. Hoffmann-La Roche: Opportunity assessment
Exhibit 38: GlaxoSmithKline: Key highlights
Exhibit 39: GlaxoSmithKline: Strength assessment
Exhibit 40: GlaxoSmithKline: Strategy assessment
Exhibit 41: GlaxoSmithKline: Opportunity assessment
Exhibit 42: MedImmune: Key highlights
Exhibit 43: MedImmune: Strength assessment
Exhibit 44: MedImmune: Strategy assessment
Exhibit 45: MedImmune: Opportunity assessment
Exhibit 46: Pfizer: Key highlights
Exhibit 47: Pfizer: Strength assessment
Exhibit 48: Pfizer: Strategy assessment
Exhibit 49: Pfizer: Opportunity assessment


F.Hoffmann-La Roche, GlaxoSmithKline, Medlmmune, Pfizer, ADMA Biologics, Amgen, Anthera Pharmaceuticals, Bayer HealthCare, Biogen, Biotest, Bristol-Myers Squibb, Celgene, Immunomedics, Kedrion Biopharma, LFB Group, Merck, Novartis, Shire, Takeda Pharmaceuticals, and UCB.





★調査レポート[ループス治療の世界市場2017-2021] (Global Lupus Therapeutic Market 2017-2021 / IRTNTR13460)販売に関する免責事項
[ループス治療の世界市場2017-2021] (Global Lupus Therapeutic Market 2017-2021 / IRTNTR13460)についてEメールでお問い合わせ